Viatris (WBO:MYL) Debt-to-EBITDA

: -65.89 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viatris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1,850 Mil. Viatris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €14,996 Mil. Viatris's annualized EBITDA for the quarter that ended in Dec. 2023 was €-256 Mil. Viatris's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -65.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Viatris's Debt-to-EBITDA or its related term are showing as below:

WBO:MYL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.04 Med: 4.75 Max: 13.13
Current: 5.22

During the past 13 years, the highest Debt-to-EBITDA Ratio of Viatris was 13.13. The lowest was 3.04. And the median was 4.75.

WBO:MYL's Debt-to-EBITDA is ranked worse than
82.65% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs WBO:MYL: 5.22

Viatris Debt-to-EBITDA Historical Data

The historical data trend for Viatris's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

4.80

13.13

5.22

3.04

5.22

Viatris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA																1.96	3.97	4.05	3.81	-65.89

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Viatris's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Viatris's Debt-to-EBITDA falls into.

Viatris Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viatris's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1850.231	+	14996.159)	/	3224.63
	=	5.22

Viatris's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1850.231	+	14996.159)	/	-255.66
	=	-65.89

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Viatris (WBO:MYL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Viatris Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Viatris's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (WBO:MYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines